Ferinject® in Patient With Thrombocytosis Secondary to Inflammatory Bowel Disease (IBD)

NCT00882414 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

26

Enrollment

INDUSTRY

Sponsor class

Stopped Main objective of study was met. Further recruitment was difficult.

Conditions

Thrombocytosis
Iron-Deficiency Anemia

Interventions

DRUG: FERINJECT® (Ferric carboxymaltose)
DRUG: Placebo

Sponsor

Vifor Pharma